Bolt Biotherapeutics, Inc. (BOLT)

Market Cap	16.29M
Revenue (ttm)	7.69M
Net Income (ttm)	-63.12M
Shares Out	38.34M
EPS (ttm)	-1.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	202,249
Open	0.4400
Previous Close	0.4395
Day's Range	0.4250 - 0.4527
52-Week Range	0.3820 - 1.5600
Beta	0.94
Analysts	Hold
Price Target	1.13 (+165.88%)
Earnings Date	Mar 24, 2025

About BOLT

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: BOLT
• Website: https://www.boltbio.com

Financial Performance

In 2024, Bolt Biotherapeutics's revenue was $7.69 million, a decrease of -2.36% compared to the previous year's $7.88 million. Losses were -$63.12 million, -8.79% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for BOLT stock is "Hold." The 12-month stock price forecast is $1.13, which is an increase of 165.88% from the latest price.

Price Target

$1.13

(165.88% upside)

Analyst Consensus: Hold